ABC | Volume 114, Nº4, April 2020

Brief Communication Miranda et al. Ranolazine and type 3 long QT syndrome Arq Bras Cardiol. 2020; 114(4):732-735 Figure 2 – Action of ranolazine (RANO) in ENDO and EPI cardiomyocytes exposed to ATX-II and paced at 0.2 Hz. Representative traces of calcium transients (upper traces) and cardiomyocyte sarcomere shortening (lower traces) following exposure to Tyrode’s solution (i), 6 nM ATX-II (ii), 6 nM ATX-II + 30 µM RANO (iii), 6 nM ATX-II (iv), and 6 nM ATX-II + 10 µM TTX (iv) in ENDO (A) and EPI (D) cells. Time to 90% of Ca2+ reuptake in ENDO (n = 8 cells) (B) and EPI (n = 6 cells) (E). Time to 90% sarcomere relaxation in ENDO (C) and EPI (F) cells. * p < 0.05 compared to the ATX-II group. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This study was funded by FAPESP nº 2014/09861-1. Study Association This article is part of the thesis of master submitted by Victor Martins Miranda, from Universidade Federal de São Paulo . Ethics approval and consent to participate This study was approved by the Ethics Committee of the CEUA UNIFESP under the protocol number 2435/70816. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Erratum In the Brief Communication “Inotropic and Antiarrhythmic Transmural Actions of Ranolazine in a Cellular Model of Type 3 Long QT Syndrome”, with DOI number: https://doi.org/10.36660/abc.20190220 , published in the periodical Arquivos Brasileiros de Cardiologia, 114(4):732-735, on page 732: consider Danilo Roman-Campos as the correct form for the name of the author Danilo Roman Campos. 734